At LogiPharma USA 2026, quality leaders explained why connected data, risk-based prioritization, and human accountability must come before AI in supply chain compliance.
|Articles|May 17, 2021
Disruption without interruption: Transitioning Rare Disease HUB & NCP Programs
Author(s)RareMed Solutions
Transitioning a rare disease HUB or NCP program to a rare-focused partner can yield major service quality improvements without program disruption.
Advertisement
Advertisement
Related to this article
Swisslog's Mark Beers discusses how software helps pharma supply chains adapt to shifting portfolios, strengthen inventory verification and build trust.
At LogiPharma USA 2026, leaders from J&J, Sun Pharma, Accord Healthcare, and Freehand discussed visibility, redundancy tradeoffs, and AI's role in resilient pharma supply chains.
McKesson's Chris Van Norman previews his LogiPharma USA keynote on demand signal sharing, AI, and precision distribution for targeted therapies.
LogiPharma's Charleen Ring and McKesson's Chris Van Norman preview the 2026 agenda, sessions to prioritize and a day two fireside chat.
Cardinal Health and McKesson moved to extend CVS Health distribution deals through June 2032, retaining their largest customer pending final contracts.
Inside the October 2026 issue: why splitting MMR takes years, why payers cite a price that does not bind them, and what pricing rules broke.
Mike Hennessy Jr. on the commercial assumptions being rewritten across pricing, patient engagement and supply chain in PC's October 2026 print issue.
Advertisement
Advertisement